Analytes/procedures in
bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).
Additional Information
The interpretive criteria for HER2 immunohistochemistry performed on gastroesophageal adenocarcinomas differs significantly from breast carcinoma. The GHER2 program will help participating laboratories understand these differences.
Program Information
- One 10‑core tissue microarray slide
Shipping Schedule
-
Shipment A: March 23
-
Shipment B: August 17